Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

NCT02887625 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether a combination of two diabetes medications (exenatide and pioglitazone) works better than insulin alone in adults with poorly controlled type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 410 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2015-02 · est. completion 2017-05

Where 1 site · Qatar

What this study is testing ClinicalTrials.gov NCT02887625 ↗

Description as written by the study sponsor.

To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea

Treatments tested

Pioglitazone plus exenatide also known as actos and bydureon Drug

pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
insulin glargine and insulin aspart also known as lantus Drug

the dose will be escalated to maintain HbA1c \<7.0%

Main thing measured	HbA1c
Sponsor	Dr. Muhammad Abdulghani
Conditions studied	Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02887625 ↗